Research Topics
| ROBERT GRIGGSSummaryAffiliation: University of Rochester Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathiesDaniel Platt
School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY 14642 0669, USA
Arch Neurol 69:527-9. 2012....
The current status of treatment for inclusion-body myositisRobert C Griggs
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Neurology 66:S30-2. 2006..However, because high-dose prednisone worsens strength while decreasing inflammation but increases amyloid accumulation, alternative targets for intervention and novel treatment strategies are needed...
Clinical research for rare disease: opportunities, challenges, and solutionsRobert C Griggs
Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 203, Rochester, NY 14620, USA
Mol Genet Metab 96:20-6. 2009....
Markesbery disease: autosomal dominant late-onset distal myopathy: from phenotype to ZASP gene identificationRobert C Griggs
Department of Neurology, University of Rochester School of Medicine and Dentistry, 1351 Mt Hope Avenue, Suite 203, Rochester, NY 14620, USA
Neuromolecular Med 13:27-30. 2011..Thus, Markesbery disease is a zaspopathy. Other families have been identified with the same mutation and a shared haplotype indicating a founder effect...
Inclusion body myositisRabi Tawil
Department of Neurology, University of Rochester, Rochester, New York 14642, USA
Curr Opin Rheumatol 14:653-7. 2002..The treatment of IBM with conventional immunosuppressive agents has been disappointing. Therapeutic approaches currently under study or consideration are beta-interferon and synthetic anabolic hormones...
Treatment of idiopathic inflammatory myopathiesAnthony A Amato
Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Curr Opin Neurol 16:569-75. 2003..This article reviews the results of recent therapeutic trials in dermatomyositis, polymyositis, and inclusion body myositis and suggests an approach to treating patients with inflammatory myopathy...
Pivotal studies of orphan drugs approved for neurological diseasesJun Mitsumoto
College of Physicians and Surgeons, Columbia University, New York, NY, USA
Ann Neurol 66:184-90. 2009..To identify design elements of clinical trials leading to US Food and Drug Administration approval of drugs for neurological diseases with and without orphan indications...
Unicorns, dragons, polymyositis, and other mythological beastsAnthony A Amato
Neurology 61:288-9. 2003
Research Grants
- Dichlorphenamide vs Acetazolamide for Periodic ParalysisROBERT GRIGGS; Fiscal Year: 2004....
- Dichlorphenamide vs Acetazolamide for Periodic ParalysisROBERT GRIGGS; Fiscal Year: 2009..abstract_text> ..
- Novel Designs and Outcome Measures for Bench to Bedside Research on NMDROBERT GRIGGS; Fiscal Year: 2007..In this effort to provide new treatments for neuromuscular disease, this conference will help to further public health goals. ..
- Nervous System Channelopathies: Pathogenesis & TreatmentROBERT GRIGGS; Fiscal Year: 2007..They may also offer a window for understanding common disorders likely to be caused by CNS channel mutations/dysfunction such as migraine and epilepsy. ..
- EXPERIMENTAL THERAPEUTICS IN NEUROLOGICAL DISEASEROBERT GRIGGS; Fiscal Year: 2007..Training facilities include: the General Clinical Research Center, Clinical Trials Coordination Centers, Biostatistics Department, Gorell Molecular Biology Laboratory, Center for Aging & Developmental Biology. ..
- Novel treatment for muscle disease: Fueling the pipeline and finding the productROBERT GRIGGS; Fiscal Year: 2006....
- Plan forTrial to find Optimum Steroid Regimen in Duchenne Muscular DystrophyROBERT GRIGGS; Fiscal Year: 2006....
- Pathogenesis and treatment of the periodic paralysesROBERT GRIGGS; Fiscal Year: 2004....
- Dichlorphenamide vs Acetazolamide for Periodic ParalysisROBERT GRIGGS; Fiscal Year: 2007..abstract_text> ..
- Dichlorphenamide vs Acetazolamide for Periodic ParalysisRobert C Griggs; Fiscal Year: 2010..abstract_text> ..
